FDA published a perspective article in JAMA that describes the agency’s current regulatory thinking for the development of CAR T-cell therapies.
This week’s oncology headlines run the gamut—from a discussion on the long-term consequences of 9/11 on lung cancer incidence, to the promise—and limits—of cutting edge mRNA science, to major institutional leadership changes, and even the intersection of cancer and war.
